Jeffrey M Jacobson

Summary

Affiliation: Drexel University College of Medicine
Country: USA

Publications

  1. doi request reprint Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19104, USA
    J Infect Dis 198:1345-52. 2008
  2. pmc Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Antimicrob Agents Chemother 53:450-7. 2009
  3. pmc Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Infect Dis 201:1481-7. 2010
  4. pmc Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
    Antimicrob Agents Chemother 54:4137-42. 2010
  5. pmc Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures
    Gregory C Antell
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
    Retrovirology 13:32. 2016
  6. pmc HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity
    Michael R Nonnemacher
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 11:e0150835. 2016
  7. pmc Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences
    Benjamas Aiamkitsumrit
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 9:e107389. 2014
  8. pmc Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status
    Will Dampier
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
    J Neurovirol . 2016
  9. pmc HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed Patients
    Will Dampier
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 11:e0155382. 2016
  10. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010

Collaborators

Detail Information

Publications23

  1. doi request reprint Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19104, USA
    J Infect Dis 198:1345-52. 2008
    ..The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro...
  2. pmc Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Antimicrob Agents Chemother 53:450-7. 2009
    ..In conclusion, ibalizumab administered either weekly or biweekly was safe and well tolerated and demonstrated antiviral activity. Further studies with ibalizumab in combination with standard antiretroviral treatments are warranted...
  3. pmc Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Infect Dis 201:1481-7. 2010
    ..This study is the first to evaluate subcutaneous administration...
  4. pmc Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
    Antimicrob Agents Chemother 54:4137-42. 2010
    ..The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent...
  5. pmc Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures
    Gregory C Antell
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
    Retrovirology 13:32. 2016
    ....
  6. pmc HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity
    Michael R Nonnemacher
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 11:e0150835. 2016
    ....
  7. pmc Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences
    Benjamas Aiamkitsumrit
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 9:e107389. 2014
    ....
  8. pmc Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status
    Will Dampier
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
    J Neurovirol . 2016
    ..The implication of these results is that niVpr variants alter the genesis and/or progression of HAND through differences in Vpr-mediated effects in the peripheral blood and/or the brain...
  9. pmc HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed Patients
    Will Dampier
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 11:e0155382. 2016
    ..Determining the factors that affect HIV-1 mutation rates in the peripheral blood may lead to elucidation of the mechanisms associated with changes in HIV-1 disease severity. ..
  10. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010
    ..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
  11. pmc The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
    Jeffrey M Jacobson
    Division of Infectious Diseased and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA Division of Infectious Diseases, University of Colorado, Denver, CO Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA Profectus BioSciences, Inc, Tarrytown, NY Department of Immunology and Microbiology, Rush University School of Medicine, Chicago, IL Department of Neurology, Washington University School of Medicine, St Louis, MO HIV AIDS Division, University of California, San Francisco, CA Social and Scientific Systems, Inc, Silver Springs, MD Division of AIDS, NIAID, Bethesda, MD Frontier Science, Amherst, NY and Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 71:163-71. 2016
    ..The Profectus Biosciences multiantigen (MAG) HIV-1 DNA vaccine encodes HIV-1 Gag/Pol, Nef/Tat/Vif, and Envelope, and interleukin-12 (IL-12) and is delivered by electroporation combined with intramuscular injection (IM-EP)...
  12. pmc Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohort
    Nirzari Parikh
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA Center for Clinical and Translational Medicine, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA and Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA
    J Acquir Immune Defic Syndr 66:256-64. 2014
    ....
  13. pmc Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial
    Benigno Rodriguez
    Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University University Hospitals of Cleveland, Cleveland, OH Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA University of Pittsburgh, Pittsburgh, PA Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD Department of Medicine, Rush University Medical Center, Chicago, IL ViroStatics srl, Sassari, Italy Genetic Immunity, Budapest, Hungary Genetic Immunity, McLean, VA and Social and Scientific Systems, Inc, Silver Spring, MD
    J Acquir Immune Defic Syndr 64:351-9. 2013
    ..DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses...
  14. doi request reprint Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial
    Noah McKittrick
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Intern Med 158:19-26. 2013
    ..HIV-infected persons have less robust antibody responses to influenza vaccines...
  15. pmc Combinatorial approaches to the prevention and treatment of HIV-1 infection
    Vanessa Pirrone
    Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, New College Building, Philadelphia PA 19102, USA
    Antimicrob Agents Chemother 55:1831-42. 2011
    ..The shift in focus within the microbicide development field from single compounds to combination approaches is also explored...
  16. pmc Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Division of Hematology and Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada Department of Epidemiology and Biostatistics, Drexel University College of Medicine, Philadelphia, PA Argostherapeutics, Durham, NC Division of Infectious Diseases, the Ottawa Hospital and the University of Ottawa, Ottawa, CA Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA Department of Medicine, Albert Einstein College of Medicine, New York, NY Clinique Medicale du Quartier Latin, Montreal, Quebec, Canada Duke University Medical Center, Durham, NC UNC HIV Cure Center and Departments of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC Clinique Medicale l Actuel, Montreal, Quebec, Canada and Frontier Science, Amherst, NY
    J Acquir Immune Defic Syndr 72:31-8. 2016
    ..AGS-004 amplifies translation-competent RNA molecules encoding for Gag, Rev, Vpr, and Nef from the patient's autologous virus and loads them into dendritic cells...
  17. pmc Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
    Livio Azzoni
    1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
    J Infect Dis 207:213-22. 2013
    ..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication...
  18. ncbi request reprint Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Zahida Parveen
    Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Curr HIV Res 5:281-92. 2007
    ..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
  19. pmc Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions
    Arangassery Rosemary Bastian
    Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, 245N 15th Street, New College Building, Room No, 11102, Philadelphia, PA 19102, USA
    Retrovirology 10:153. 2013
    ..We examined the underlying mechanism of action of the peptide triazole thiol, KR13 that has been shown previously to specifically bind gp120, block cell receptor site interactions and potently inhibit HIV-1 infectivity...
  20. pmc A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA AIDS Clinical Trials Group, Statistical and Data Analysis Center, Harvard University School of Public Health, Boston, MA Vaccine and Gene Therapy Institute, Port Saint Lucie, FL Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI Department of Immunology Microbiology, Rush University School of Medicine, Chicago, IL Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, CA Division of Infectious Diseases, Department of Medicine, University of California, San Diego, School of Medicine, San Diego, CA Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN Social and Scienti x fb01 c Systems, Inc, Silver Springs, MD Frontier Sciences, Buffalo, NY and Division of AIDS, NIAID, Bethesda, MD
    J Acquir Immune Defic Syndr 66:399-406. 2014
    ..Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease...
  21. pmc Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection
    Joseph A Fraietta
    Department of Microbiology and Immunology, Center for Immunology and Vaccine Science, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS Pathog 9:e1003658. 2013
    ....
  22. pmc Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy
    Brandon Palermo
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    HIV Clin Trials 12:222-7. 2011
    ..To better characterize the relationship between body mass index (BMI) and CD4+ T-lymphocyte recovery in HIV disease...
  23. pmc Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment
    Luna Li
    Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, MS 1013A, Philadelphia, PA 19102, USA
    J Neurovirol 17:92-109. 2011
    ....